FHL1 and cardiac hypertrophy: More molecular studies confirmed that empagliflozin ameliorates the expression of cardiac hypertrophy markers such as actin alpha (ACTA1), four-and-a-half LIM domains 1 (FHL1), myosin light chain 2a (MLC2A) in high-glucose-exposed human-induced pluripotent stem cells-derived cardiomyocytes [66].